Search Browse Earnings

Contineum Therapeutics, Inc.

Nasdaq:CTNM

Pharmaceutical Preparations·SAN DIEGO, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Contineum Therapeutics, Inc. — SlamSEC

Revenue

$50.0M

FY 2024

Adj. EBITDA

-$50.6M

-101.3% margin

FY 2025

Net Income

-$42.3M

-84.5% margin

FY 2025

EPS (Diluted)

-$2.18

FY 2025

Stock Price

$13.84

+0.8%

2026-03-06

52W Range

$3.35 – $16.33

P/E Ratio

-6.3x

Market Cap

$319.7M

Cash

$21.9M

FY 2025

Total Debt

—

Net Cash

$21.9M

FY 2024

Enterprise Value

$297.7M

Debt / EBITDA

0.4x

FY 2024

EV / EBITDA

-5.9x

Employees

—

CEO

Stengone Carmine N.